SARS-CoV-2 has never appeared on the Select Agent List. The original SARS coronavirus is there. So is a chimera built by splicing SARS-CoV virulence factors into SARS-CoV-2. The virus that shut the country down is not on the list and never has been.
That is not a scandal; the list controls possession and transfer of known hazards, and it does that job. It is a fact about scope. We have let one list stand in for two maps: the biological threat, and the workforce that answers to it. Both are smaller than the territory.
Nobody is keeping the other list
At the end of 2024, 8,902 people in the entire country held approval to access biological select agents and toxins. ODNI’s June 2026 vetting report records 334,263 in-access eligibility determinations for national security-sensitive positions in fiscal 2024, determinations rather than a census. Neither answers the hiring manager’s real question: how many Americans can both interpret a genome and read a classified cable. I could find no public dataset that reports it. A compliance registry is not a workforce strategy.
I have worked in that gap, first at Sandia National Laboratories on a Q clearance and later building disease detection systems for the Defense Threat Reduction Agency. This is the map I wish someone had handed me.
Where the jobs are
Fort Detrick, MD is the center of gravity: USAMRIID on medical countermeasures; DHS’s National Biodefense Analysis and Countermeasures Center, operated by Battelle, on bioforensics and threat characterization; and DIA’s National Center for Medical Intelligence, which DoD Instruction 6420.01 makes the Department’s lead activity for medical intelligence. Beyond Detrick, DTRA runs the Biological Threat Reduction Program. Acquisition runs through the Capability Program Executive Chemical, Biological, Radiological and Nuclear Defense, formerly the JPEO. Sandia and the other Energy Department laboratories carry real bioscience portfolios. CIA hires science, technology, and weapons analysts to work against foreign weapons programs, and the FBI leads the federal response to WMD threats at home.
These are mission areas, not a promise of an open billet, and not every biological role needs a clearance. The practical advice: stop searching “microbiology.” Search biodefense, medical intelligence, biosecurity, computational biology, and threat characterization. The work is posted under words biologists do not use.
What the jobs actually require
Analyst billets in the intelligence centers generally run at Top Secret with SCI access; program and acquisition billets typically run at Secret. Then comes the layer most of the cleared world never sees. A clearance and select agent access approval are different determinations; neither substitutes for the other. Under 42 CFR 73.10, no one may access a select agent without approval following a security risk assessment by the Attorney General; in practice the FBI’s Bioterrorism Risk Assessment Group runs them. In military laboratories, DoD Instruction 5210.88 adds the Biological Personnel Reliability Program for anyone with access to Tier 1 agents. None of that is decoration: the Amerithrax investigation attributed the worst biological attack in American history to an insider at a federal laboratory.
The Trusted Workforce progress review reports 92 days for an initial Secret and 205 for an initial Top Secret for the fastest 90% of cases, first-quarter fiscal 2026 data. That covers investigation and adjudication only, not initiation, SCI indoctrination, or polygraph, where much of the real wait lives. Offer to badge runs materially longer than 205 days.
What transfers, and what does not
More transfers than either side assumes, and less than a recruiter hopes. Cleared cyber and intelligence professionals arrive with reasoning under uncertainty and anomaly investigation. An insider threat professional already understands personnel reliability, the heart of select agent security. What does not transfer is the science: no analyst becomes an epidemiologist by substituting genomes for log files, and no bench scientist becomes an analyst without training in adversary assessment. Stop writing job descriptions that demand a senior biologist, intelligence analyst, engineer, and compliance officer in one person.
Nobody can say how thin the pipeline is
The shortage everyone asserts has never been measured, which makes every explanation a hypothesis, starting with citizenship. NSF reports temporary visa holders earned 25.3% of 2024 U.S. biological and biomedical doctorates among recipients who reported citizenship status, against 61.1% in computer science and 53.9% in engineering. The remainder combines citizens and permanent residents, and access generally requires citizenship with narrow exceptions, so the figures do not prove three quarters are eligible. They do prove the domestic share in biology dwarfs the fields the cleared world recruits from hardest. Whatever limits this workforce, it is not a shortage of Americans earning biology doctorates. Measure the demand side first: titles scientists never search, reluctance to sponsor, onboarding no one owns.
Why the map is about to change
In September 2026 congressional appropriators disclosed a proposed iteragency agreement between the NIH and Defense Department that would route infectious disease research funds toward defense programs. Appropriators have serious objections to how it was done; those deserve their own argument. The practical consequence is plain: work drifting from university laboratories toward defense institutions drifts toward the places where clearances, reliability programs, and counterintelligence support already exist. The credential stack above stops being a niche concern and becomes the entry requirement.
For cleared professionals, the crossover is real and the scarce asset is the clearance you already hold. For hiring managers, sponsorship follows a government requirement, a contract with a DD-254 or a designated sensitive position; where it exists, initiate it rather than filtering for someone already cleared. For the policy community, count the workforce; ODNI’s vetting report could add a discipline cut. The select agent list still has a job. It was never a workforce plan, and the next biological event will not wait for an adjudication to close.
Disclosure: The author has no financial interest in any organization, vendor, or program named in this article, and no funding supported it.
